CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma
Phase II Trial of CHOP-Rituximab Augmented With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma
Sponsor: Bayer
Terminated
Accrual was too slow. Trial terminated
Other terminated trials from Bayer
Other Lymphoma, B-Cell trials with similar outcome
Listed as NCT00455897, this PHASE2 trial focuses on Lymphoma, B-Cell and Lymphoma, Diffuse and remains terminated or withdrawn. Sponsored by Bayer, it has been updated 7 times since 2006, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Terminated PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Terminated PHASE2
-
Jun 2018 — Jan 2021 [monthly]
Terminated PHASE2
-
Feb 2018 — Jun 2018 [monthly]
Terminated PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Feb 2018 [monthly]
Terminated PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Terminated PHASE2
First recorded
Dec 2006
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Bayer
- Beth Israel Deaconess Medical Center
- Brigham and Women's Hospital
- Dana-Farber Cancer Institute
- Massachusetts General Hospital
For direct contact, visit the study record on ClinicalTrials.gov .